Other Vaccines - France

France

Highlights

In France, the revenue in the Other Vaccines market is estimated to reach US$1.25bn by the year 2024.
It is expected that the revenue will have an annual growth rate (CAGR 2024-2029) of 9.78%, leading to a market volume of US$2.00bn by 2029.
When comparing globally, United States is projected to generate the highest revenue in this market, amounting to US$24.73bn in 2024.
France has seen a surge in demand for other vaccines, driven by increased awareness of the importance of immunization in preventing diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in France has been experiencing some interesting developments in recent times.

Customer preferences: Customers in France have shown a growing interest in vaccines that target diseases other than the common ones like measles, mumps, and rubella. This shift in preference can be attributed to the growing awareness about the importance of vaccination in preventing diseases and the availability of more vaccines in the market.

Trends in the market: One of the major trends in the Other Vaccines market in France is the increasing demand for vaccines that target diseases like HPV, meningitis, and shingles. This trend can be attributed to the growing awareness about the importance of preventing these diseases and the availability of more effective vaccines. Another trend in the market is the growing importance of travel vaccines, as more people travel abroad for work or leisure.

Local special circumstances: One of the special circumstances in France is the high level of government involvement in the healthcare sector. The French government provides universal healthcare coverage, which includes coverage for vaccines. This has led to a high vaccination rate in the country, which has in turn created a favorable environment for the Other Vaccines market.

Underlying macroeconomic factors: One of the underlying macroeconomic factors that is driving the growth of the Other Vaccines market in France is the growing healthcare expenditure in the country. France has one of the highest healthcare expenditures in the world, which has led to the development of a robust healthcare infrastructure. This infrastructure has created a favorable environment for the development and distribution of vaccines in the country. Additionally, the growing aging population in France has also contributed to the growth of the Other Vaccines market, as older individuals are more susceptible to certain diseases that can be prevented through vaccination.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.